Rituximab News and Research

RSS

Rituximab is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of B-cell non-Hodgkin lymphoma. It is also approved to be used with methotrexate to treat rheumatoid arthritis. Rituximab is also being studied in the treatment of other types of cancer and other conditions.

GlaxoSmithKline initiates study of PROMACTA in chronic idiopathic thrombocytopenic purpura

GlaxoSmithKline has announced the initiation of a global, open-label, single group trial that will assess the efficacy, safety and tolerability of PROMACTA (eltrombopag olamine) in patients previously treated for chronic idiopathic thrombocytopenic purpura (ITP).

15 Apr 2007

Rituximab shown to significantly inhibit structural damage of joints caused by rheumatoid arthritis

New data presented at the EULAR meeting (European League Against Rheumatism) show for the first time that MabThera (rituximab), a unique B cell targeted therapy, is able to significantly inhibit structural damage of joints caused by rheumatoid arthritis (RA).

27 Jun 2006

The efficacy and safety of Rituximab in patients with active rheumatoid arthritis

Drugs aimed at suppressing inflammation-provoking cytokines--specifically those linked to T-cells--have improved the treatment of rheumatoid arthritis (RA), a chronic, inflammatory autoimmune disease. Still, the frequency of remission achieved by these biologic agents remains below 50 percent.

3 May 2006

Natural killer cells and antibody-based immune function

A new drug may boost the effectiveness of a widely used treatment for patients with non-Hodgkin lymphoma (NHL), while simultaneously overcoming drug resistance in those patients.

4 Apr 2006

Novel therapy for chronic graft-versus-host disease

A study by Dana-Farber Cancer Institute researchers offers the strongest evidence yet of the effectiveness of a novel therapy for chronic graft-versus-host disease (GVHD), a potentially life-threatening complication of donor bone marrow and stem cell transplants.

28 Mar 2006

Novel therapy for chronic graft-versus-host disease (GVHD) using Rituximab

Dana-Farber researchers found that rituximab reduced the severity of chronic graft-versus-host disease (GVHD) in 70 percent of the study participants.

27 Mar 2006

Study to Rituximab's potential to preserve insulin production in newly diagnosed type 1 diabetics

A drug used to treat lymphoma, rheumatoid arthritis and other immune disorders may enable newly-diagnosed type 1 diabetics to save some of their pancreas function and thereby reduce their susceptibility to long-term complications.

20 Mar 2006

FDA approves Rituxan (Rituximab)

Rituxan is the first treatment for RA that selectively targets immune cells known as CD20-positive B-cells. Through this unique mechanism of action, Rituxan may affect multiple pathways by which B-cells are believed to contribute to the initiation and development of RA.

1 Mar 2006

Rituximab maintenance therapy dramatically improves survival for patients with lymphoma

Two years of maintenance therapy with rituximab dramatically improves the chances of survival for patients suffering from one of the most frequent forms of lymphoma, indolent non-Hodgkin's Lymphoma (NHL).

14 Feb 2006

Targeted cancer therapies: Another step forward

While it is clear that the treatment of cancer has already begun to undergo a paradigm shift with the inclusion of innovative targeted therapies into current regimens, it would be wrong to assume these products will entirely replace traditional chemotherapy as the standard treatment for cancer sufferers.

22 Dec 2005

Targeted cancer therapies: Another step forward

22 Dec 2005

New treatment advances for patients with follicular lymphoma

A newly published study recommends that doctors carefully choose their patients' initial therapies because there are significant differences in overall survival rates, according to researchers at the University of Rochester Medical Center's James P. Wilmot Cancer Center.

20 Oct 2005

New monoclonal antibody that targets immune system B cells shows promise for treating leukemias

In studies with mice, treatment with a new monoclonal antibody that targets immune system B cells has shown considerable promise for treating leukemias, autoimmune diseases and transplant rejection, according to immunologists at Duke University Medical Center.

11 Oct 2005

Experimental vaccine can prime the immune system to help fight an aggressive form of lymphoma

Researchers at The University of Texas M. D. Anderson Cancer Center and the National Cancer Institute have found that an experimental vaccine can prime the immune system to help fight an aggressive form of lymphoma, even though prior therapy had eliminated virtually all of the B cells thought necessary to mount such a defense.

22 Aug 2005

MabThera highly effective in treating rheumatoid arthritis

Results from the DANCER study presented today revealed that MabThera significantly improves symptoms in heavily treated patients who are affected by moderate-to-severe rheumatoid arthritis (RA), a painful and debilitating disease of the joints.

9 Jun 2005

Rituximab, used to treat rheumatoid arthritis (RA) is safe and effective

Professor Paul Emery from the University of Leeds in the UK led the DANCER study (Double blind placebo controlled dose ranging study), designed to confirm the efficacy of rituximab for the treatment of patients with active RA who have failed to improve on one or more disease modifying anti-rheumatic drugs (DMARDs).

9 Jun 2005

Rituximab provides new hope for people with lupus

Rheumatologists at the Annual European Congress of Rheumatology in Vienna, Austria heard today (Thursday 9 June) that rituximab is the first drug in a quarter of a century that is making a real impact, and an alternative to previous standard treatments of high-dose steroids, and chemotherapy.

9 Jun 2005

Radioimmunotherapy streamlines non-Hodgkin's lymphoma treatment

Researchers at the Keck School of Medicine of the University of Southern California and colleagues have found a way to streamline a new form of treatment for patients with non-Hodgkin's lymphoma.

18 May 2005

FDA knocks back anticancer drug Marqibo

Inex Pharmaceuticals announced today that United States Food and Drug Administration (FDA) provided an action letter detailing that the anticancer drug Marqibo (vincristine sulfate liposomes injection) is "not approvable" under the FDA's accelerated approval regulations based on the phase 2 clinical trial data submitted.

19 Jan 2005

GlaxoSmithKline acquires full marketing and development rights for BEXXAR worldwide

GlaxoSmithKline announced that it has reached an agreement with Corixa Corporation to acquire worldwide rights and responsibilities related to the manufacturing, development and commercialization of the BEXXAR® therapeutic regimen.

14 Dec 2004

Rituximab News and Research

GlaxoSmithKline initiates study of PROMACTA in chronic idiopathic thrombocytopenic purpura

Rituximab shown to significantly inhibit structural damage of joints caused by rheumatoid arthritis

The efficacy and safety of Rituximab in patients with active rheumatoid arthritis

Natural killer cells and antibody-based immune function

Novel therapy for chronic graft-versus-host disease

Novel therapy for chronic graft-versus-host disease (GVHD) using Rituximab

Study to Rituximab's potential to preserve insulin production in newly diagnosed type 1 diabetics

FDA approves Rituxan (Rituximab)

Rituximab maintenance therapy dramatically improves survival for patients with lymphoma

Targeted cancer therapies: Another step forward

Targeted cancer therapies: Another step forward

New treatment advances for patients with follicular lymphoma

New monoclonal antibody that targets immune system B cells shows promise for treating leukemias

Experimental vaccine can prime the immune system to help fight an aggressive form of lymphoma

MabThera highly effective in treating rheumatoid arthritis

Rituximab, used to treat rheumatoid arthritis (RA) is safe and effective

Rituximab provides new hope for people with lupus

Radioimmunotherapy streamlines non-Hodgkin's lymphoma treatment

FDA knocks back anticancer drug Marqibo

GlaxoSmithKline acquires full marketing and development rights for BEXXAR worldwide

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News